Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

ARS Pharmaceuticals (SPRY) Capital Expenditures (2021 - 2025)

ARS Pharmaceuticals (SPRY) has disclosed Capital Expenditures for 5 consecutive years, with -$5.5 million as the latest value for Q3 2025.

  • Quarterly Capital Expenditures fell 4043.57% to -$5.5 million in Q3 2025 from the year-ago period, while the trailing twelve-month figure was $339000.0 through Dec 2025, down 39.79% year-over-year, with the annual reading at $339000.0 for FY2025, 39.79% down from the prior year.
  • Capital Expenditures hit -$5.5 million in Q3 2025 for ARS Pharmaceuticals, down from $5.8 million in the prior quarter.
  • In the past five years, Capital Expenditures ranged from a high of $5.8 million in Q2 2025 to a low of -$5.5 million in Q3 2025.
  • Historically, Capital Expenditures has averaged $70052.6 across 5 years, with a median of $84000.0 in 2023.
  • Biggest YoY gain for Capital Expenditures was 15081.58% in 2025; the steepest drop was 4043.57% in 2025.
  • Year by year, Capital Expenditures stood at -$767000.0 in 2021, then soared by 125.95% to $199000.0 in 2022, then tumbled by 57.79% to $84000.0 in 2023, then soared by 259.52% to $302000.0 in 2024, then crashed by 1928.15% to -$5.5 million in 2025.
  • Business Quant data shows Capital Expenditures for SPRY at -$5.5 million in Q3 2025, $5.8 million in Q2 2025, and $91000.0 in Q1 2025.